Dianthus Therapeutics to Participate in Two Upcoming Investor Events
Provided By GlobeNewswire
Last update: Apr 29, 2025
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at two upcoming investor events.
Read more at globenewswire.com
